DIACC-3010 is under clinical development by Evexta Bio and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DIACC-3010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DIACC-3010 overview
DIACC-3010 is under development for the treatment of gastric cancer and aggressive lymphomas. The drug candidate is administered through the oral route. It is a dual inhibitor of p70S6K/Akt1/3. It is a new chemical entity.
The drug candidate was under development for the treatment of triple negative breast cancer, gastric cancer, HER2 positive and negative metastatic breast cancer, colon cancer, adenocystic carcinoma of the salivary gland (third line), recurrent small-cell lung cancer (third line), ovarian cancer (second line), pancreatic cancer (second line), glioblastoma multiforme (GBM), pancreatic cancer and small-cell lung cancer.
Evexta Bio overview
Evexta Bio is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutic approaches in oncology. Its main activities carry out the research and development of novel cancer treatments. The company’s products include rupitasertib, an optimized S6K inhibitor, and EVX020, an antibody-drug conjugate program. Evexta Bio’s products are designed for applications in treating various cancer types, including breast cancer, glioblastoma multiforme, gastric cancer, and hematologic malignancies. Its products are targeted towards healthcare providers and institutions involved in cancer treatment. The company operates primarily within the biotechnology and pharmaceutical sectors, with a focus on clinical trials and therapeutic development. Evexta Bio is headquartered in Paris, France.
For a complete picture of DIACC-3010’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
